In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Robert F. Kennedy has espoused a number of unorthodox views on public health, most notably questioning the safety and ...

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

The FDA already has cleared COVID-19 vaccines tweaked to better target omicron as boosters for everyone 5 and older. Pfizer's says its COVID-19 vaccine was 73% effective in protecting children ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Although Merck’s vaccine, like Pfizer’s, is approved for use in people at least 18 years of age, Capvaxive is the only pneumococcal disease vaccine that was specifically made to protect adults ...

The Food and Drug Administration expanded its approval of Pfizer’s vaccine for a deadly respiratory virus to a new age group. The vaccine, called Abrysvo, has been approved for the prevention of ...

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...